1-苄氧羰基哌啶-4-甲酰胺 | 167757-45-1

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄氧羰基哌啶-4-甲酰胺
• 中文别名: 1-Cbz-哌啶-4-甲酰胺
• 英文名称: benzyl 4-carbamoylpiperidine-1-carboxylate
• 英文别名: 4-Carbamoylpiperidine-1-carboxylic acid benzyl ester；benzyl 4-(aminocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate
• CAS: 167757-45-1
• 化学式: C₁₄H₁₈N₂O₃
• mdl: MFCD01568760
• 分子量: 262.309
• InChiKey: UNJWOPBEKPMSGH-UHFFFAOYSA-N

物化性质

• 熔点：
  130 °C
• 沸点：
  475.5±44.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Name:	Benzyl 4-(aminocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate Material Safety Data Sheet
Synonym:
CAS:	167757-45-1

Section 1 - Chemical Product MSDS Name:Benzyl 4-(aminocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
167757-45-1	Benzyl 4-(aminocarbonyl)tetrahydro-1(2	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 167757-45-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 130 - 132 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H18N2O3
Molecular Weight: 262.31

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 167757-45-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzyl 4-(aminocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 167757-45-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 167757-45-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 167757-45-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  N-Cbz-哌啶-4-羧酸	1-benzyloxycarbonylpiperidine-4-carboxylic acid	10314-98-4	C14H17NO4	263.293
  1-Cbz-4-哌啶甲酸甲酯	methyl-1-benzyloxycarbonyl-4-piperidinecarboxylate	138163-07-2	C15H19NO4	277.32

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  4-[氨基(硫代羰基)]哌啶-1-羧酸苄酯	benzyl 4-carbamothioylpiperidine-1-carboxylate	167757-46-2	C14H18N2O2S	278.375
  1-N-Cbz-4-氰基哌啶	benzyl 4-cyanopiperidine-1-carboxylate	161609-84-3	C14H16N2O2	244.293

反应信息

• 作为反应物：
  描述：

  1-苄氧羰基哌啶-4-甲酰胺 在 三乙胺 、 ethanaminium,N-(difluoro-λ⁴-sulfanylidene)-N-ethyl-,tetrafluoroborate 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 以63%的产率得到1-N-Cbz-4-氰基哌啶
  参考文献：
  名称：

  用XtalFluor-E从醛肟和伯酰胺合成腈

  摘要：

  摘要 描述了使用[Et 2 NSF 2 ] BF 4（XtalFluor-E）的醛肟和酰胺的脱水反应，用于合成腈。总的来说，反应在室温下在环境友好的溶剂（EtOAc）中快速进行（通常<1小时），仅含有少量过量的脱水剂（1.1当量）。可以制备各种腈，包括手性非外消旋腈。另外，在许多情况下，后处理后不需要进一步纯化腈。 描述了使用[Et 2 NSF 2 ] BF 4（XtalFluor-E）的醛肟和酰胺的脱水反应，用于合成腈。总的来说，反应在室温下在环境友好的溶剂（EtOAc）中快速进行（通常<1小时），仅含有少量过量的脱水剂（1.1当量）。可以制备各种腈，包括手性非外消旋腈。另外，在许多情况下，后处理后不需要进一步纯化腈。

  DOI：

  10.1055/s-0034-1378881
• 作为产物：
  描述：

  1-Cbz-4-哌啶甲酸甲酯 在 ammonium hydroxide 作用下， 以 水 为溶剂， 反应 16.0h， 生成 1-苄氧羰基哌啶-4-甲酰胺
  参考文献：
  名称：

  用XtalFluor-E从醛肟和伯酰胺合成腈

  摘要：

  摘要 描述了使用[Et 2 NSF 2 ] BF 4（XtalFluor-E）的醛肟和酰胺的脱水反应，用于合成腈。总的来说，反应在室温下在环境友好的溶剂（EtOAc）中快速进行（通常<1小时），仅含有少量过量的脱水剂（1.1当量）。可以制备各种腈，包括手性非外消旋腈。另外，在许多情况下，后处理后不需要进一步纯化腈。 描述了使用[Et 2 NSF 2 ] BF 4（XtalFluor-E）的醛肟和酰胺的脱水反应，用于合成腈。总的来说，反应在室温下在环境友好的溶剂（EtOAc）中快速进行（通常<1小时），仅含有少量过量的脱水剂（1.1当量）。可以制备各种腈，包括手性非外消旋腈。另外，在许多情况下，后处理后不需要进一步纯化腈。

  DOI：

  10.1055/s-0034-1378881

文献信息

• Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
  申请人：Zhao Cunxiang

  公开号：US20050234046A1

  公开（公告）日：2005-10-20

  Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  芳基磺酰胺和磺酰基化合物作为过氧化物酶体增殖激活受体的调节剂，包含它们的药物组合物，以及使用它们治疗疾病的方法被披露。
• Imidazopyrazines as protein kinase inhibitors
  申请人：Zhao Lianyun

  公开号：US20070117804A1

  公开（公告）日：2007-05-24

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的咪唑吡嗪化合物，作为蛋白质和/或检查点激酶的抑制剂，包括制备这类化合物的方法、包含一个或多个这类化合物的药物组合物、制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与蛋白质或检查点激酶相关的一个或多个疾病的方法。
• THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS
  申请人：Pulici Maurizio

  公开号：US20130324551A1

  公开（公告）日：2013-12-05

  Thiazolylphenyl-benzenesulfonamido derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了规范中定义的式（I）的噻唑基苯基磺酰胺衍生物及其药学上可接受的盐，其制备方法和包含它们的药物组合物；本发明的化合物可能在治疗中对治疗与蛋白激酶活性失调相关的疾病，如癌症，具有用处。
• Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect
  作者：Maurizio Pulici、Gabriella Traquandi、Chiara Marchionni、Michele Modugno、Rosita Lupi、Nadia Amboldi、Elena Casale、Nicoletta Colombo、Luca Corti、Marina Fasolini、Fabio Gasparri、Wilma Pastori、Alessandra Scolaro、Daniele Donati、Eduard Felder、Arturo Galvani、Antonella Isacchi、Enrico Pesenti、Marina Ciomei

  DOI：10.1002/cmdc.201402424

  日期：2015.2

  oncogenesis. As part of a project aimed at finding inhibitors of B‐Raf, a key player in the MAPK cascade, we originally identified a thiazole derivative endowed with high potency and selectivity, optimal in vitro ADME properties, and good pharmacokinetic profiles in rodents, but that suffers from elevated hERG inhibitory activity. An optimization program was thus undertaken, focused mainly on the elaboration

  在人类癌症中经常观察到有丝分裂原激活的蛋白激酶（MAPK）介导的途径组分RAF-MEK-ERK的异常激活，并且明显促进了肿瘤的发生。作为旨在寻找MAPK级联关键参与者B-Raf抑制剂的项目的一部分，我们最初确定了噻唑衍生物，该噻唑衍生物具有很高的效价和选择性，最佳的体外ADME特性，并且在啮齿动物中具有良好的药代动力学特征，但是患有高水平的hERG抑制活性。因此，进行了优化程序，主要集中在脚手架的R 1和R 2基团的加工上。这种努力最终导致了N-（4- 2-（1-环丙基哌啶-4-基）-4-4- [3-（2,5-二氟苯磺酰基氨基）-2-氟苯基]噻唑-5-基}-吡啶-2-基）乙酰胺（20），可保持良好的体外和体内特性，但缺乏hERG责任。除了仅对带有B-Raf V600E或V600D突变的细胞系表现出有效的抗增殖活性外，化合物20还令人感兴趣地显示，与其他已知的B-Raf抑制剂相比，非突变B
• Amidine compounds
  申请人：Japan Tobacco Inc.

  公开号：US06562828B1

  公开（公告）日：2003-05-13

  A compound of the formula [I] wherein R1, R2 and R3 are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention, a salt thereof and a prodrug thereof are useful as factor Xa inhibitor and blood coagulation inhibitor, and are useful for the prophylaxis and/or treatment of diseases caused by blood coagulation or thrombus.

  其中R1、R2和R3相同或不同，且每个都是氢原子，其中每个符号如规范中定义，其盐或前药。本发明的化合物及其盐和前药可用作因子Xa抑制剂和抗凝血剂，对于预防和/或治疗由血液凝固或血栓引起的疾病有用。